Abstract
Topic Existing evidence for the safety of repeated low-level red-light (RLRL) therapy for myopia control.
Clinical relevance Recent trials show RLRL therapy is effective in the prevention and control of myopia. Establishing its safety profile is necessary prior to widespread clinical implementation.
Methods We conducted a systematic review (International Prospective Register of Systematic Reviews, CRD42024516676) of articles across seven databases from inception through February 10, 2024, with keywords related to myopia and RLRL therapy. Pooled safety outcomes and risk-to-benefit ratios were reported, and incidence of side effects was compared with other anti-myopia interventions. Quality appraisal was performed using the Cochrane Risk of Bias Tool.
Results Among 689 screened articles, 20 studies (2.90%; eleven randomized controlled trials, four non-randomized controlled trials, one post-trial study, one single-arm study, one retrospective study and two case reports of identical patient.; median duration 9 months, longest 24 months) were analysed, encompassing 2,380 participants aged 3-18 years and 1,436 individuals undergoing RLRL therapy. Two case reports described an identical patient with reversible decline in visual acuity and optical coherence tomography (OCT) abnormalities, completely resolved 4 months after treatment cessation. No cases of permanent vision loss were reported. Temporary afterimage was the most common ocular symptom following treatment, resolving within 6 minutes in reported studies. The number needed to harm outweighed the number needed to treat by a ratio of 12.7-21.4 for a person with −3D to −8D myopia treated with RLRL therapy. Incidence of side effects from RLRL was 0.088 per 100 patient-years (95% confidence interval [CI], 0.02-0.50), comparable to spectacles designed for myopia reduction (0.22; 95% CI, 0.09-0.51; P=0.385), and significantly lower than for low-dose atropine (7.32; 95% CI, 6.65-8.05; P<0.001), orthokeratology (20.6; 95% CI, 16.7-25.0; P<0.001), other anti-myopia contact lens (19.3; 95% CI, 17.6-21.1; P<0.001).
Conclusion No irreversible visual function loss or ocular structural damage was identified with RLRL. Fundus photography and OCT before and during therapy, alongside home monitoring of visual acuity and duration of afterimages, are necessary to identify side effects. Further adequately-powered studies of longer duration are needed to evaluate long-term safety of RLRL.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024516676
Funding Statement
This research was funded by the National Natural Science Foundation of China (82371086).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a systematic review, and we searched the data from seven databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, the Chinese databases China National Knowledge Infrastructure and VIP Information Database, from their dates of inception through 10 February 2024. All research adhered to the tenets of the Declaration of Helsinki. Individual patient-level consent was not required, nor was ethical review.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-first authors.
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations and Acronyms
- RLRL
- repeated low-level red-light
- OCT
- optical coherence tomography
- CI
- confidence interval
- IMI
- International Myopia Institute
- RCT
- randomized controlled trial
- SER
- spherical equivalent refraction
- AL
- axial length
- NNH
- number needed to harm
- NNT
- number needed to treat
- SVS
- single-vision spectacles
- BCVA
- best-corrected visual acuity.
